In addition, ET patients displayed higher numbers of EMPs (27% of MPs in ET patients versus 1% in controls), i.e., CD62E(+) (p = 0.007) and CD144(+) (p = 0.021), as well as GMPs, i.e., CD66b(+) and CD66acde(+), or MMPs, i.e., CD14(+). The gene discussed is CDH5; the disease is essential thrombocythemia.